Nephros (NEPH) Liabilities and Shareholders Equity (2010 - 2026)

Nephros has reported Liabilities and Shareholders Equity for 17 years, with the latest figure at $15.8 million in Q2 2026.

• On a quarterly basis, Liabilities and Shareholders Equity rose 28.81% year-over-year to $15.8 million in Q2 2026; TTM through Jun 2026 was $56.5 million, a 23.75% increase from a year earlier, with the FY2025 full-year figure at $13.6 million, up 21.69% from the prior year.
• Liabilities and Shareholders Equity was $15.8 million for Q2 2026 at Nephros, up from $13.8 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $15.8 million in Q2 2026, with the low at $10.4 million in Q2 2023.
• Average Liabilities and Shareholders Equity over 5 years is $12.3 million, with a median of $11.6 million recorded in 2024.
• The sharpest annual moves came in 2022 and 2026: Liabilities and Shareholders Equity slumped 37.68% in 2022, then rose 28.81% in 2026.
• Over 5 years, Liabilities and Shareholders Equity stood at $11.0 million in 2022, then grew by 7.84% to $11.9 million in 2023, then decreased by 5.49% to $11.2 million in 2024, then climbed by 21.69% to $13.6 million in 2025, then rose by 15.61% to $15.8 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $15.8 million (Q2 2026), $13.8 million (Q1 2026), and $13.6 million (Q4 2025), per Business Quant data.